Safety and Tolerability of NXY-059 for Acute Intracerebral Hemorrhage
نویسندگان
چکیده
منابع مشابه
Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial.
BACKGROUND AND PURPOSE NXY-059 is a free radical-trapping neuroprotectant developed for use in acute ischemic stroke. To facilitate prompt administration of treatment, potentially before neuroimaging, we investigated the safety of NXY-059 in patients with intracerebral hemorrhage (ICH). METHODS We randomized 607 patients within 6 hours of acute ICH to receive 2270 mg intravenous NXY-059 over ...
متن کاملNXY-059 for acute ischemic stroke.
BACKGROUND NXY-059 is a free-radical-trapping agent that is neuroprotective in animal models of stroke. We tested whether it would reduce disability in humans after acute ischemic stroke. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 1722 patients with acute ischemic stroke who were randomly assigned to receive a 72-hour infusion of placebo or intravenous...
متن کاملTolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke.
BACKGROUND AND PURPOSE Increased free radical formation contributes to the damage caused to the brain by acute ischemia. NXY-059 is a nitrone-based free radical trapping agent in development for acute stroke. NXY-059 has neuroprotective efficacy when given 5 hours after onset of transient focal ischemia in the rat. METHODS This was a randomized, double-blind, placebo-controlled, parallel grou...
متن کاملTolerability of NXY-059 at higher target concentrations in patients with acute stroke.
BACKGROUND AND PURPOSE NXY-059 is a nitrone-based free radical-trapping agent in development for acute stroke. In patients with acute stroke, NXY-059 is well tolerated at concentrations known to be associated with neuroprotection in animal models of transient cerebral ischemia; however, higher target concentrations appear necessary on the basis of animal models of permanent ischemia. METHODS ...
متن کاملCosmic implications of NXY-059.
The SAINT studies on NXY-0591,2 have reinvigorated debate over the momentous issues of neuroprotection and the development of novel stroke therapeutics. Some may argue there is little new ground that NXY-059 has unearthed and, in fact, the clinical trials merely confirm that as a strategy, neuroprotection has not been shown to be effective. Editorials in high-profile journals have sent out the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stroke
سال: 2007
ISSN: 0039-2499,1524-4628
DOI: 10.1161/strokeaha.106.472746